Analyzing Novartis (NVS) and Its Competitors

Novartis (NYSE:NVS – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Novartis to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.

Volatility & Risk

Novartis has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Novartis’ competitors have a beta of -0.04, meaning that their average stock price is 104% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Novartis and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis 3 9 6 0 2.17
Novartis Competitors 7845 13798 25818 1039 2.41

Novartis presently has a consensus target price of $152.25, indicating a potential downside of 6.04%. As a group, “Pharmaceuticals” companies have a potential upside of 23.83%. Given Novartis’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Novartis has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

13.1% of Novartis shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dividends

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novartis pays out 58.8% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 49.2% of their earnings in the form of a dividend. Novartis lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.

Earnings & Valuation

This table compares Novartis and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Novartis $54.53 billion $13.98 billion 30.92
Novartis Competitors $18.73 billion $3.24 billion 559.25

Novartis has higher revenue and earnings than its competitors. Novartis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Novartis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novartis 18.11% 41.04% 14.45%
Novartis Competitors -2,398.26% -203.62% -15.08%

Summary

Novartis competitors beat Novartis on 9 of the 15 factors compared.

Novartis Company Profile

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.